CP-346086 is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC₅₀ of 2.0 nM for human and rodent MTP. CP-346086 can lower plasma cholesterol and triglycerides in vivo.

CP-346086 (0.1-1000 nM) dose-dependently inhibits human MTP-mediated triglyceride transfer between vesicles with an IC₅₀ of 2.0 nM.
CP-346086 (24 h) inhibits apolipoprotein B (apoB) and triglyceride secretion (IC₅₀=2.6 nM) from Hep-G2 cells without affecting apoA-I secretion or lipid synthesis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

CP-346086 (1-100 mg/kg; oral gavage once daily for 2 weeks) reduces plasma total, VLDL, and LDL cholesterol and triglycerides in mice.
CP-346086 (25 mg/kg; a single p.o.) results in an almost complete inhibition of Tyloxapol-induced triglyceride accumulation in fasted rats.
CP-346086 (0.1-10 mg/kg; a single p.o.) reduces acute plasma triglyceride in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

CP-346086 (1-100 mg/kg; oral gavage once daily for 2 weeks) reduces plasma total, VLDL, and LDL cholesterol and triglycerides in mice.
CP-346086 (25 mg/kg; a single p.o.) results in an almost complete inhibition of Tyloxapol-induced triglyceride accumulation in fasted rats.
CP-346086 (0.1-10 mg/kg; a single p.o.) reduces acute plasma triglyceride in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Chandler CE, et, al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res. 2003 Oct;44(10):1887-901.  [Content Brief]